Literature DB >> 8605725

Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis.

J G Conway1, S J Trexler, J A Wakefield, B E Marron, D L Emerson, D M Bickett, D N Deaton, D Garrison, M Elder, A McElroy, N Willmott, A J Dockerty, G M McGeehan.   

Abstract

Four potent, synthetic inhibitors of matrix metalloproteinases (MMPs) were assessed as inhibitors of tumor growth and spontaneous metastasis to the lung. Mat Ly Lu rat prostate tumor, LOX human melanoma and M27 murine Lewis lung tumor were implanted subcutaneously (s.c.) in mice and allowed to grow for 3-12 days. The lungs of the tumor-bearing mice were then removed and implanted s.c. into untreated mice, and the outgrowth of secondary tumors from the implanted lungs measured. The incidence and rate of outgrowth of secondary tumors increased with the length of primary tumor growth, validating these measurements as indices of spontaneous metastasis to the lung. Compounds were tested by s.c. implantation of minipumps which delivered compound throughout the period of primary tumor growth and spontaneous metastasis to the lung at steady-state drug concentrations orders of magnitude greater than the concentrations needed to either inhibit collagenase, gelatinase or stromelysin in vitro. Inhibitor treatment slowed the growth of primary s.c. Mat Ly Lu and LOX tumors by 40-60% but had no significant effect on the growth of primary M27 tumors. Surprisingly, inhibitor treatment had no significant effect on the ability of the lung to generate secondary tumors when reimplanted s.c. in untreated mice. Because of the possible importance of cathepsins B, H and L in tumor growth and metastasis, the irreversible inhibitor E-64 was also infused by s.c. minipump. E-64 had no effect on the growth or spontaneous metastasis of Mat Ly Lu or M27 tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605725     DOI: 10.1007/bf00121208

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  38 in total

1.  Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases.

Authors:  O A Alvarez; D F Carmichael; Y A DeClerck
Journal:  J Natl Cancer Inst       Date:  1990-04-04       Impact factor: 13.506

Review 2.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

3.  Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo.

Authors:  S Hashida; T Towatari; E Kominami; N Katunuma
Journal:  J Biochem       Date:  1980-12       Impact factor: 3.387

4.  Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor.

Authors:  D J Dykes; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

5.  Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; R J Muschel; E N Hughes
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

6.  L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L.

Authors:  A J Barrett; A A Kembhavi; M A Brown; H Kirschke; C G Knight; M Tamai; K Hanada
Journal:  Biochem J       Date:  1982-01-01       Impact factor: 3.857

7.  Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology.

Authors:  M Polette; C Clavel; M Cockett; S Girod de Bentzmann; G Murphy; P Birembaut
Journal:  Invasion Metastasis       Date:  1993

8.  A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts.

Authors:  B Davies; P D Brown; N East; M J Crimmin; F R Balkwill
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

9.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.

Authors:  C Pyke; E Ralfkiaer; P Huhtala; T Hurskainen; K Danø; K Tryggvason
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

10.  Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue.

Authors:  M E Stearns; M Wang
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

View more
  9 in total

1.  Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.

Authors:  Hideo Maki; Kanji Hojo; Hidekazu Tanaka; Takuko Yamada Sawada; Ryuji Maekawa; Takayuki Yoshioka
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Type IV collagen levels are elevated in the serum of patients with peritoneal dissemination of gastric cancer.

Authors:  Jun Kinoshita; Sachio Fushida; Shinichi Harada; Isamu Makino; Keishi Nakamura; Katsunobu Oyama; Hideto Fujita; Itasu Ninomiya; Takashi Fujimura; Masato Kayahara; Tetsuo Ohta
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

3.  Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor.

Authors:  R Maekawa; H Maki; T Wada; H Yoshida; K Nishida-Nishimoto; H Okamoto; Y Matsumoto; H Tsuzuki; T Yoshioka
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover.

Authors:  Marianna De Colli; Paolo Tortorella; Guya Diletta Marconi; Mariangela Agamennone; Cristina Campestre; Marilena Tauro; Amelia Cataldi; Susi Zara
Journal:  Clin Oral Investig       Date:  2015-12-22       Impact factor: 3.573

5.  Detection of gelatinase B activity in serum of gastric cancer patients.

Authors:  Vesna V Dragutinović; Nebojsa S Radovanović; Lidija T Izrael-Zivković; Miroslav M Vrvić
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

6.  Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.

Authors:  D M Ignar; J L Andrews; S M Witherspoon; J D Leray; W C Clay; K Kilpatrick; J Onori; T Kost; D L Emerson
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

7.  Detection of type IV collagenase activity in malignant ascites.

Authors:  Xiao-Min Sun; Wei-Guo Dong; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

8.  Proteolysis in human breast and colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

Review 9.  Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma.

Authors:  Salvatore Napoli; Chiara Scuderi; Giuseppe Gattuso; Virginia Di Bella; Saverio Candido; Maria Sofia Basile; Massimo Libra; Luca Falzone
Journal:  Cells       Date:  2020-05-07       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.